Merck KGaA (MKGAF) News Today $143.30 +1.25 (+0.88%) (As of 12/20/2024 05:55 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Merck KGaA (OTCMKTS:MKGAF) Hits New 1-Year Low - Should You Sell?Merck KGaA (OTCMKTS:MKGAF) Sets New 12-Month Low - Here's WhyDecember 19 at 6:44 PM | marketbeat.comMerck posts mixed late-stage trial results for HIV treatmentDecember 19 at 7:48 AM | msn.comMerck enters obesity drug race in pact with Chinese pharma HansohDecember 18 at 11:43 AM | seekingalpha.comStrong Fundamentals And Weight Loss Entry Make Merck (MRK) A BuyDecember 18 at 11:43 AM | msn.comMerck KGaA (OTCMKTS:MKGAF) Trading Up 0.8% - Here's What HappenedMerck KGaA (OTCMKTS:MKGAF) Stock Price Up 0.8% - Here's WhyDecember 13, 2024 | marketbeat.comMerck reinstated with a Buy at BofADecember 10, 2024 | markets.businessinsider.comShort Interest in Merck KGaA (OTCMKTS:MKGAF) Grows By 19.7%Merck KGaA (OTCMKTS:MKGAF - Get Free Report) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 284,600 shares, a growth of 19.7% from the October 15th total of 237,800 shares. Based on an average daily volume of 300 shares, the days-to-cover ratio is currently 948.7 days.November 17, 2024 | marketbeat.comMerck KGaA (MKGAF) Q3 2024 Earnings Call Highlights: Strong Organic Growth Amid Currency HeadwindsNovember 15, 2024 | uk.finance.yahoo.comMerck KGaA (MKGAF) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comMerck KGaA Earnings Growth Beats ExpectationsNovember 14, 2024 | wsj.comMerck KGaA: Phase III Trial Of Pimicotinib In Tenosynovial Giant Cell Tumor Meets Primary EndpointNovember 13, 2024 | markets.businessinsider.comMerck narrows outlook; Keytruda drives Q3 beat despite Gardasil impactOctober 31, 2024 | seekingalpha.comMerck KGaA (OTCMKTS:MKGAF) Short Interest UpdateMerck KGaA (OTCMKTS:MKGAF - Get Free Report) was the target of a large decrease in short interest in September. As of September 30th, there was short interest totalling 193,700 shares, a decrease of 23.5% from the September 15th total of 253,200 shares. Based on an average trading volume of 200 shares, the short-interest ratio is currently 968.5 days.October 15, 2024 | marketbeat.comMerck KGaA (0O14) Receives a Buy from JefferiesOctober 4, 2024 | markets.businessinsider.comMerck: Favezelimab/Keytruda Combo Study Misses Goal in Colorectal CancerSeptember 25, 2024 | marketwatch.comMerck Says Phase 3 KEYFORM-007 Study Did Not Meet Primary Goal Of Overall SurvivalSeptember 25, 2024 | markets.businessinsider.comMerck fails in late-stage trial for Keytruda combo in colon cancerSeptember 25, 2024 | seekingalpha.comMerck says trial of combination treatment for colon cancer failed to meet main goalSeptember 25, 2024 | msn.comMerck KGaA (OTCMKTS:MKGAF) Lifted to Strong-Buy at The Goldman Sachs GroupThe Goldman Sachs Group upgraded Merck KGaA to a "strong-buy" rating in a report on Thursday.September 20, 2024 | marketbeat.comWhy Did Merck Stock Rise 65%?September 6, 2024 | forbes.comMerck KGaA (OTCMKTS:MKGAF) Hits New 12-Month High at $196.92Merck KGaA (OTCMKTS:MKGAF) Reaches New 1-Year High at $196.92August 28, 2024 | marketbeat.comMerck wins EU nod for rare lung disease drug WinrevairAugust 26, 2024 | seekingalpha.comMerck KGaA (OTCMKTS:MKGAF) Shares Pass Above 50-Day Moving Average of $174.28Merck KGaA (OTCMKTS:MKGAF) Share Price Crosses Above 50 Day Moving Average of $174.28August 16, 2024 | marketbeat.comMerck: Buy This Bargain Before It's GoneAugust 12, 2024 | seekingalpha.comMerck KGaA (OTCMKTS:MKGAF) Share Price Passes Below Fifty Day Moving Average of $174.29Merck KGaA (OTCMKTS:MKGAF) Shares Cross Below Fifty Day Moving Average of $174.29August 6, 2024 | marketbeat.comMerck KGaA Profit Falls After Cancer Drug Candidate DroppedAugust 1, 2024 | morningstar.comMerck reports earlier-than-expected improvement in semiconductor marketAugust 1, 2024 | msn.comMerck KGaA (OTCMKTS:MKGAF) Sees Large Decline in Short InterestMerck KGaA (OTCMKTS:MKGAF - Get Free Report) saw a large decrease in short interest during the month of July. As of July 15th, there was short interest totalling 432,200 shares, a decrease of 16.2% from the June 30th total of 515,600 shares. Based on an average daily volume of 400 shares, the days-to-cover ratio is currently 1,080.5 days.July 28, 2024 | marketbeat.comMerck's RSV therapy meets main goal of study in infantsJuly 23, 2024 | yahoo.comMerck defeats appeal by nearly 1,200 shingles vaccine plaintiffsJuly 19, 2024 | reuters.comMerck KGaA (OTCMKTS:MKGAF) Share Price Crosses Below 50-Day Moving Average of $175.08Merck KGaA (OTCMKTS:MKGAF) Shares Cross Below Fifty Day Moving Average of $175.08July 16, 2024 | marketbeat.comMerck KGaA (OTCMKTS:MKGAF) Stock Crosses Below Fifty Day Moving Average of $174.97Merck KGaA (OTCMKTS:MKGAF) Stock Price Passes Below 50 Day Moving Average of $174.97July 6, 2024 | marketbeat.comMerck KGaA (OTCMKTS:MKGAF) Stock Crosses Below 50 Day Moving Average of $174.19Merck KGaA (OTCMKTS:MKGAF) Shares Pass Below 50-Day Moving Average of $174.19June 28, 2024 | marketbeat.comMerck KGaA shares slump on neck cancer trial failureJune 25, 2024 | proactiveinvestors.comMerck KGaA (OTCMKTS:MKGAF) Hits New 52-Week High at $193.63Merck KGaA (OTCMKTS:MKGAF) Hits New 1-Year High at $193.63June 12, 2024 | marketbeat.comMerck KGaA (OTCMKTS:MKGAF) Sets New 1-Year High at $189.65Merck KGaA (OTCMKTS:MKGAF) Sets New 1-Year High at $189.65June 5, 2024 | marketbeat.comShort Interest in Merck KGaA (OTCMKTS:MKGAF) Drops By 29.8%Merck KGaA (OTCMKTS:MKGAF - Get Free Report) was the recipient of a large drop in short interest in May. As of May 15th, there was short interest totalling 479,100 shares, a drop of 29.8% from the April 30th total of 682,700 shares. Based on an average trading volume of 700 shares, the days-to-cover ratio is presently 684.4 days.May 31, 2024 | marketbeat.comMerck KGaA (OTCMKTS:MKGAF) Reaches New 1-Year High at $188.06Merck KGaA (OTCMKTS:MKGAF) Reaches New 52-Week High at $188.06May 23, 2024 | marketbeat.comMerck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024May 23, 2024 | businesswire.comMerck KGaA (OTCMKTS:MKGAF) Stock Passes Above Fifty Day Moving Average of $167.89Merck KGaA (OTCMKTS:MKGAF) Shares Pass Above 50 Day Moving Average of $167.89May 23, 2024 | marketbeat.comAulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007May 15, 2024 | businesswire.comMerck KGaA (OTCMKTS:MKGAF) Short Interest Up 23.8% in AprilMerck KGaA (OTCMKTS:MKGAF - Get Free Report) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 682,700 shares, a growth of 23.8% from the April 15th total of 551,400 shares. Based on an average daily trading volume, of 400 shares, the days-to-cover ratio is presently 1,706.8 days.May 15, 2024 | marketbeat.comMerck KGaA's Q1 adjusted profit declines less than fearedMay 15, 2024 | reuters.comMerck says Keytruda failed as first-line therapy for uterine cancerMay 9, 2024 | msn.comMerck KGaA's Dividend AnalysisApril 29, 2024 | finance.yahoo.comMerck KGaA (ETR:MRK) Is Due To Pay A Dividend Of €2.20April 28, 2024 | finance.yahoo.comShareholders Will Most Likely Find Merck KGaA's (ETR:MRK) CEO Compensation AcceptableApril 20, 2024 | finance.yahoo.comMerck KGaA's (ETR:MRK) investors will be pleased with their favorable 74% return over the last five yearsApril 15, 2024 | finance.yahoo.comMerck to test lung cancer combo therapy in late-stage trialApril 4, 2024 | msn.comMerck KGaA (OTCMKTS:MKGAF) Stock Passes Above 50 Day Moving Average of $168.61Merck KGaA (OTCMKTS:MKGAF) Shares Cross Above 50-Day Moving Average of $168.61March 29, 2024 | marketbeat.com Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKGAF and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy. Click to get the name and ticker symbol MKGAF Media Mentions By Week MKGAF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MKGAF News Sentiment▼-0.340.60▲Average Medical News Sentiment MKGAF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MKGAF Articles This Week▼41▲MKGAF Articles Average Week Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKGAF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News Takeda Pharmaceutical News UCB News UCB News Alnylam Pharmaceuticals News Bayer Aktiengesellschaft News Merck KGaA News Teva Pharmaceutical Industries News Astellas Pharma News BeiGene News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:MKGAF) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck KGaA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.